BiOrion Technologies, Zealand Pharma and Akademiska Sjukhuset Uppsala receive a EUROSTARS grant for their € 1.8 M fibrosis imaging program BONIFIB

September 26, 2017

Groningen, The Netherlands, September 26, 2017


The EUROSTARS grant of a EUR 1.8 million fibrosis imaging program is awarded to a multidisciplinary consortium including BiOrion Technologies BV, Zealand Pharma A/S and Akademiska Sjukhuset, PET Centre, University Uppsala. EUROSTARS is a joint program between EUREKA and the European Commission, co-funded from the national budgets of 36 EUROSTARS Participating States and Partner Countries and by the European Union through Horizon 2020. The subsidy is for a three-year period and will allow clinical development of a PDGF beta receptor binding bicyclic peptide conjugated to a PET radionuclide to image hepatic fibrosis.


Herman Steen, CEO of BiOrion, “We are delighted with the recognition and support for our PDGF beta receptor binding bicyclic peptide drug-targeting program by EUROSTARS. This strong and synergistic consortium will enable BiOrion to progress clinical development of our novel targeted therapeutics against fibrosis, not only in liver.”


About BiOrion Technologies
BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic diseases. These diseases include cardiac fibrosis and hepatic fibrosis, and fibrosis-associated cancers such as colorectal cancer. BiOrion’s platform and drug development engine is based on proprietary PDGF-ß-receptor binding bicyclic peptides that act as targeting vehicles for diagnostic PET radionuclides and (existing) anti-fibrotic therapeutics.


About Zealand Pharma
Zealand Pharma A/S was founded in 1997 and is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand Pharma intends to be a leader in specialty medicines focusing on metabolic and gastrointestinal diseases and other specialty disease areas with significant unmet medical needs.


About Akademiska Sjukhuset, PET Centre
Akademiska Sjukhuset is a leading University hospital in Sweden with 8000 employees. The PET Centre at the hospital was created in 1991 and performs about 1900 clinical PET investigations per year including around 350 for clinical research, with 25 different PET tracers. PET Centre performs also research in radiochemistry and preclinical PET.


Herman Steen, PhD
CEO BiOrion Technologies BV

BiOrion concluded investment by Carduso Capital



Groningen, The Netherlands, November 11, 2016


BiOrion Technologies BV has raised funding from Carduso Capital for its clinical validation program in fibrosis.

BiOrion Technologies BV (BiOrion), a biopharmaceutical drug discovery company, develops products for the diagnosis and treatment of fibrosis. Fibrosis is a consequence of chronic cycles of tissue injury and repair, leading to the accumulation of scar tissue in affected organs and disruption of normal tissue architecture and function. Fibrosis is the final common pathway in virtually all forms of chronic organ failure e.g. liver, lungs and kidneys, ultimately leading to organ transplantation or death.

BiOrion has raised additional capital from Carduso Capital for the clinical validation of its proprietary drug-targeting technology. In drug targeting, drugs are delivered specifically to cells that cause the disease and not to the healthy cells. Thus, such therapy will be more effective with fewer side effects. The targeting technology of BiOrion is based on the research of Prof. Dr. Klaas Poelstra of the University of Groningen. It provides opportunities to develop both drugs as well as imaging diagnostics for fibrosis, based on the same technology platform. The clinical validation study is scheduled for next year, allowing early detection of fibrosis resolution.


About BiOrion

BiOrion is a Dutch biopharmaceutical drug discovery company involved in developing targeted therapeutics and companion imaging diagnostics for myofibroblast-associated diseases, such as hepatic fibrosis, renal fibrosis, cardiac fibrosis, idiopathic pulmonary fibrosis and fibrosis-associated cancers such as colorectal cancer.

BiOrion’s platform and drug development engine is based on proprietary PDGF-ß-receptor binding bicyclic peptides. PDGF is one of the main drivers of fibrosis, and its receptor is specifically over-expressed on the key pathogenic cells: the myofibroblasts. This allows cell-specific targeting of diagnostic labels and (existing) antifibrotic drugs. For more information about BiOrion:


About Carduso Capital

Carduso Capital is an investment firm based in Groningen, The Netherlands that participates in innovative technology companies that have strong technology links with the University of Groningen (RUG) and the University Medical Centre of Groningen (UMCG) and its affiliates. Carduso Capital believes it is important to invest in innovative companies that are early stage or at a certain moment search for capital to finance their growth. Carduso Capital supports initiatives within the main themes Life Sciences and Energy and aims for long-term cooperation’s. Besides participations with capital Carduso Capital also provides proactive management support and the use of its broad international network. For more information about Carduso Capital: